Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content
  • QuiremSpheres® has been shown in clinical trials to be safe1,2 and efficacious2 for the treatment of unresectable liver cancer
  • QuiremSpheres® is shipped in a ready-to-use patient-specific vial. There is no need for patient-dose preparation on-site.
  • QuiremSpheres® can be visualized with high accuracy (MRI) and high sensitivity (SPECT) after the treatment to verify dose delivery
  • QuiremSpheres® comes with Q-Suite dosimetry software, tailored for evaluating 166Ho SIRT.
  • We offer you an extensive QuiremSpheres® training program, including proctoring by a SIRT clinical expert, to ensure a seamless first treatment experience

Q-Suite™

  • Post-treatment Dosimetry: High resolution MRI; high accuracy SPECT
  • Voxel-wise dose calculation: Dose-point kernel, convolution method 
  • Fusion: Measure dose to tissue using CT or MR 
  • Integrated reporting: Export key data in a PDF report
  • Easy-to-use: Intuitive workflow based user interface
Read more Read less

​QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.

​Characteristics
QuiremSpheres®Other SIRT products
IsotopeHolmium-166​Yt-90
Beta-radiation (Emax)1.77 MeV (48.7%)
1.85 MeV (50.0%)
2.28 MeV
Gamma-radiation81 keV (6.7%)-
Visible on MRIYesNo
Half-life26.8 hours64.1 hours
MaterialPoly(L-lactic acid)Resin (r) or glass (g)
Diameter15-60 μm20-60 μm (r) 
20-30 μm (g)
Density1.4 g/cm31.6 g/cm3 (r) 
3.3 g/cm3 (g)
​Item reference
​Material description
​Description
​QS-V001​Holmium-166 microspheres,QuiremSpheres®
​V-vial containing a patient-specific dose of QuiremSpheres®
QS-C001​Customer kit
​Set of re-usable administration box and accessories for administration of QuiremSpheres®
QS-D001​Delivery setSet of sterile single-use tube lines for administration of QuiremSpheres® (in a carton of 6 pieces)​

​QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.

QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.

QuiremSpheres® is not approved in Canada

​QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.

QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.

QuiremSpheres® is not approved in Canada

 

 

Hepar 1https://www.terumo-europe.com/en-emea/clinicaldata/hepar-1Hepar 1<p>​<sup>166</sup>Ho radioembolization is feasible and safe<sup>1</sup> for the treatment of patients with unresectable and chemorefractory liver metastases and enables image-guided treatment.</p>HayabusaArticlePage
Hepar 2https://www.terumo-europe.com/en-emea/clinicaldata/hepar-2Hepar 2<p>​Radioembolization with <sup>166</sup>Ho microspheres induced a tumor response with an acceptable toxicity profile in patients with liver metastases.</p>HayabusaArticlePage

 

 

 

 

 

 

QuiremSpheres FAQs https://www.terumo-europe.com/Relevant Product Info/QuiremSpheres FAQs.pdfQuiremSpheres FAQs 14/09/2017 22:00:00{6992E051-00C4-459A-A13D-EDA0BB7DBB07}HayabusaArticleDocument77054ba1-476b-4af3-b914-9a049e0b9ba8

1 HEPAR I: Smits et al, 2012 Lancet Oncology

HEPAR II: Prince et al, 2017 Journal of Nuclear Medicine

Did you not find the product you were looking for?